These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

192 related articles for article (PubMed ID: 17070570)

  • 21. Intraperitoneal chemotherapy and the NCI clinical announcement.
    Trimble EL; Alvarez RD
    Gynecol Oncol; 2006 Nov; 103(2 Suppl 1):S18-9. PubMed ID: 17027073
    [No Abstract]   [Full Text] [Related]  

  • 22. Chemotherapy in advanced ovarian carcinoma: current standards of care based on randomized trials.
    Thigpen T; Vance R; Puneky L; Khansur T
    Gynecol Oncol; 1994 Dec; 55(3 Pt 2):S97-107. PubMed ID: 7835816
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Optimizing primary chemotherapy in ovarian cancer.
    Markman M
    Hematol Oncol Clin North Am; 2003 Aug; 17(4):957-68, viii. PubMed ID: 12959185
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Cyclophosphamide and cisplatin versus paclitaxel and cisplatin: a phase III randomized trial in patients with suboptimal stage III/IV ovarian cancer (from the Gynecologic Oncology Group).
    McGuire WP; Hoskins WJ; Brady MF; Kucera PR; Partridge EE; Look KY; Clarke-Pearson DL; Davidson M
    Semin Oncol; 1996 Oct; 23(5 Suppl 12):40-7. PubMed ID: 8941409
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Intraperitoneal paclitaxel and cisplatin compared with dose-dense paclitaxel and carboplatin for patients with stage III ovarian cancer.
    Murphy M; Martin G; Mahmoudjafari Z; Bivona C; Grauer D; Henry D
    J Oncol Pharm Pract; 2020 Oct; 26(7):1566-1574. PubMed ID: 31948348
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Sequential single agents as first-line chemotherapy for ovarian cancer: a strategy derived from the results of GOG-132.
    Muggia FM
    Int J Gynecol Cancer; 2003; 13 Suppl 2():156-62. PubMed ID: 14656273
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Carboplatin plus paclitaxel as first-line chemotherapy in previously untreated advanced ovarian cancer. German AGO Study Group Ovarian Cancer. Arbeitsgemeinschaft Gynäkologische Onkologie.
    du Bois A; Lück HJ; Meier W; Möbus V; Costa S; Richter B; Bauknecht T; Warm M; Schroeder W; Olbricht S; Nitz U; Jackisch C
    Semin Oncol; 1997 Aug; 24(4 Suppl 11):S11-28-S11-33. PubMed ID: 9314296
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Medical therapy of advanced malignant epithelial tumours of the ovary.
    Colombo N; Parma G; Bocciolone L; Franchi D; Sideri M; Maggioni A
    Forum (Genova); 2000; 10(4):323-32. PubMed ID: 11535983
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Cost effectiveness of intraperitoneal compared with intravenous chemotherapy for women with optimally resected stage III ovarian cancer: a Gynecologic Oncology Group study.
    Havrilesky LJ; Secord AA; Darcy KM; Armstrong DK; Kulasingam S;
    J Clin Oncol; 2008 Sep; 26(25):4144-50. PubMed ID: 18757328
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Long-term survival advantage and prognostic factors associated with intraperitoneal chemotherapy treatment in advanced ovarian cancer: a gynecologic oncology group study.
    Tewari D; Java JJ; Salani R; Armstrong DK; Markman M; Herzog T; Monk BJ; Chan JK
    J Clin Oncol; 2015 May; 33(13):1460-6. PubMed ID: 25800756
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Intraperitoneal carboplatin-based chemotherapy for epithelial ovarian cancer.
    Fujiwara K; Markman M; Morgan M; Coleman RL
    Gynecol Oncol; 2005 Apr; 97(1):10-5. PubMed ID: 15790431
    [TBL] [Abstract][Full Text] [Related]  

  • 32. First-line chemotherapy for advanced ovarian cancer: paclitaxel, cisplatin and the evidence.
    Sandercock J; Parmar MK; Torri V
    Br J Cancer; 1998 Dec; 78(11):1471-8. PubMed ID: 9836480
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Long-term follow-up confirms a survival advantage of the paclitaxel-cisplatin regimen over the cyclophosphamide-cisplatin combination in advanced ovarian cancer.
    Piccart MJ; Bertelsen K; Stuart G; Cassidy J; Mangioni C; Simonsen E; James K; Kaye S; Vergote I; Blom R; Grimshaw R; Atkinson R; Swenerton K; Trope C; Nardi M; Kaern J; Tumolo S; Timmers P; Roy JA; Lhoas F; Lidvall B; Bacon M; Birt A; Andersen J; Zee B; Paul J; Pecorelli S; Baron B; McGuire W
    Int J Gynecol Cancer; 2003; 13 Suppl 2():144-8. PubMed ID: 14656271
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Combined intraperitoneal and intravenous chemotherapy for women with optimally debulked ovarian cancer: results from an intergroup phase II trial.
    Rothenberg ML; Liu PY; Braly PS; Wilczynski SP; Hannigan EV; Wadler S; Stuart G; Jiang C; Markman M; Alberts DS
    J Clin Oncol; 2003 Apr; 21(7):1313-9. PubMed ID: 12663720
    [TBL] [Abstract][Full Text] [Related]  

  • 35. ICON2 trial. EORTC-GCCG, NOCOVA, NCI-C, Scottish groups, and GOG. Gynaecologic Oncology Group.
    Piccart MJ; McGuire WP
    Lancet; 1999 Feb; 353(9152):587; author reply 588. PubMed ID: 10029002
    [No Abstract]   [Full Text] [Related]  

  • 36. Does adding intraperitoneal paclitaxel to standard intraperitoneal regimen yield incremental survival? A propensity score-matched cohort study.
    Chang YH; Lu CH; Yen MS; Lee WH; Chang Y; Chang WP; Chuang CM
    Chin J Cancer; 2016 May; 35():45. PubMed ID: 27160669
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Is there a role for intraperitoneal chemotherapy in the management of ovarian cancer?
    Markman M
    Oncology (Williston Park); 2001 Jan; 15(1):93-8; discussion 103-5. PubMed ID: 11271985
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Intraperitoneal cisplatin therapy in ovarian cancer: comparison with standard intravenous carboplatin and paclitaxel.
    Ozols RF; Bookman MA; du Bois A; Pfisterer J; Reuss A; Young RC
    Gynecol Oncol; 2006 Oct; 103(1):1-6. PubMed ID: 16904166
    [No Abstract]   [Full Text] [Related]  

  • 39. Southwest Oncology Group Trial S9912: intraperitoneal cisplatin and paclitaxel plus intravenous paclitaxel and pegylated liposomal doxorubicin as primary chemotherapy of small-volume residual stage III ovarian cancer.
    Smith HO; Moon J; Wilczynski SP; Tiersten AD; Hannigan EV; Robinson WR; Rivkin SE; Anderson GL; Liu PY; Markman M
    Gynecol Oncol; 2009 Aug; 114(2):206-9. PubMed ID: 19464730
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Weight change during chemotherapy as a potential prognostic factor for stage III epithelial ovarian carcinoma: a Gynecologic Oncology Group study.
    Hess LM; Barakat R; Tian C; Ozols RF; Alberts DS
    Gynecol Oncol; 2007 Nov; 107(2):260-5. PubMed ID: 17675142
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.